Abstract
Groups of adult male Sprague-Dawley rats were treated i.p. with 0, 0.3 and 0.5 mmole bromobenzene (BB)/kg per day in corn oil, 5 days a week for 4 weeks. Thereafter, one half of each of these groups was treated i. p. with a single acute toxic dose of 2.5 mmole BB/kg. Urines were then collected for 24 h and the animals were then sacrificed. The hepatotoxicity induced by an acute dose of BB was significantly reduced due to prior subchronic exposure to BB at 0.5 mmol/kg, but not so at 0.3 mmol/kg. These data indicate a potential tolerance against acute hepatotoxicity of BB due to prior subchronic exposure. A significant increase in the urinary excretion of thioethers or mercapturic acids of BB combined with a significant increase in the urinary level ofp-bromocatechol due to prior subchronic treatment with 0.5 mmol BB/kg relative to those due to acute treatment alone was observed. Thus enhanced bromobenzene metabolism could partly explain such potential tolerance against its acute hepatotoxicity. Such protection may also be related to certain cellular events which might occur subsequent to metabolic activation of BB.
Abbreviations
- BB:
-
bromobenzene
- SGOT:
-
Serum glutamic oxaloacetic transaminase
- SGPT:
-
Serum glutamic pyruvic transaminase
- SDH:
-
Serum sorbitol dehydrogenase
References
Chakrabarti S (1984) Increased activity of certain hepatic drug-metabolizing enzymes due to subchronic exposure to bromobenzene. Toxicol Lett 20: 79–83
Chakrabarti S, Brodeur J (1984) Dose-dependent metabolic excretion of bromobenzene and its possible relationship to hepatotoxicity in rats. J Toxicol Environ Health 14: 379–391
Conney AH (1967) Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19: 317–366
Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR (1974) Bromobenzene-induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 11: 151–169
Karmen A (1955) A note on the spectrophotometric assay of glutamic-oxaloacetic transaminase in human blood serum. J Clin Invest 34: 131–133
Lau SS, Abrams GD, Zannoni VG (1980) Metabolic activation and detoxification of bromobenzene leading to cytotoxicity. J Pharmacol Exp Ther 214: 703–708
Reid WD, Krishna G (1973) Centrilobular hepatic necrosis related to covalent binding of metabolites of halogenated aromatic hydrocarbons. Exp Mol Pathol 18: 80–95
Van Doorn R, Borm PJA, Leijdekkers CM, Henderson PT, Reuvers J, Van Bergen TJ (1980) Detection and identification of S-methylcysteine in urine of workers exposed to methyl chloride. Int Arch Occup Environ Health 46: 99–109
Zampaglione N, Jollow DJ, Mitchell FR, Stripp B, Hamrick M, Gillette JR (1973) The role of detoxifying enzymes in bromobenzene-induced liver necrosis. J Pharmacol Exp Ther 187: 218–227
Wroblewski F, La Due JS (1956) Serum glutamic-pyruvic transaminase in cardiac and hepatic disease. Proc Soc Exp Biol Med 91: 569–571
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chakrabarti, S. Potential tolerance against bromobenzene-induced acute hepatotoxicity due to prior subchronic exposure. Arch Toxicol 65, 681–684 (1991). https://doi.org/10.1007/BF02098037
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02098037